Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of IL-28B Genotype on HCV Treatment Response
NCT03090035Phase 3Completed
- Sponsor
- Sheikh Zayed Medical College
- Start
- Jan 2014
- Primary completion
- Jul 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a, ribavirin in hepatitis C (HCV), sponsored by Sheikh Zayed Medical College. Started Jan 2014; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03090035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03090035.